Killemall Plc is an established pharmaceutical company that has for many years generated 90 per cent of its revenue through the sale of two specific cold and flu remedies. Killemall has lately seen a real growth in the level of competition that it faces in its market, and demand for its products has significantly declined. To make matters worse, in the past the company has not invested sufficiently in new product development and so has been trying to remedy this by recruiting suitably trained scientific staff, but this has proved more difficult than anticipated.
In addition to recruiting staff the company also needed to invest £2m in plant and machinery. The company wanted to borrow this sum but was unable to agree suitable terms with the bank; therefore, it used its overdraft facility, which carried a higher interest rate. Consequently, some of Killemall's suppliers have been paid much later than usual and hence some of them have withdrawn credit terms, meaning the company must pay cash on delivery. As a result of the above the company's overdraft balance has grown substantially. The directors have produced a cash flow forecast and this shows a significantly worsening position over the coming 12 months. The directors have informed you that the bank overdraft facility is due for renewal next month, but they are confident that it will be renewed. They also strongly believe that the new products which are being developed will be ready to market soon, and hence trading levels will improve and therefore that the company is a going concern. They do not intend to make any disclosures in the accounts regarding going concern.

Required:
(a) Identify any potential indicators that the company is not a going concern and describe why these could impact upon the ability of the company to continue trading on a going concern basis.
(b) Explain the audit procedures that the auditor of Killemall should perform in assessing whether or not the company is a going concern.